IL1B and neoplasm: A large limitation of studies exploring the protective effect of anti-IL-1ß on doxorubicin-induced cardiotoxicity so far was that mainly non-tumor bearing mice were used, lacking the contribution of the tumor-associated inflammation on cardiac dysfunction.